A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma

被引：0
|
作者：
Cheng, A-L. [1 ]
Yen, C-J. [2 ]
Okusaka, T. [3 ]
Ikeda, M. [4 ]
Hsu, C-H. [1 ]
Wu, S-Y. [2 ]
Morizane, C. [3 ]
Hashimoto, Y. [4 ]
Ueshima, K. [5 ]
Ohtomo, T. [6 ]
Tanaka, T. [7 ]
Kudo, M. [5 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[3] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[6] Chugai Pharmaceut Co Ltd, Oncol Lifecycle Management Dept, Tokyo, Japan
[7] Chugai Pharmaceut Co Ltd, Translat Clin Res Sci & Strategy Dept, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
697P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [2] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma
    Abou-Alfa, G. K.
    Yoon, J. H.
    Modiano, M.
    Ryoo, B. Y.
    Yau, T.
    Freilich, B.
    Knox, J.
    Ly, M.
    Ahmed, H.
    Gahir, S.
    Niforos, D.
    Kowalski, M.
    Kelley, R. K.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S22 - S22
  • [4] A phase I open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Liu, Rui
    Deng, Ting
    Bai, Ming
    Zhang, Le
    Ning, Tao
    Wang, Xia
    Ji, Zhi
    Yang, Yuchong
    Ge, Shaohua
    Li, Hongli
    Duan, Jingjing
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
    Diab, Adi
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Ferry A. L. M.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Klempner, Samuel J.
    Ganguly, Bishu
    Fleener, Catherine
    Wang, Xiao
    Joh, Tenshang
    Liao, Ken
    Salek-Ardakani, Shahram
    Taylor, Carrie Turich
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 71 - 83
  • [6] Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
    Bauer, Todd M.
    Santoro, Armando
    Lin, Chia-Chi
    Garrido-Laguna, Ignacio
    Joerger, Markus
    Greil, Richard
    Spreafico, Anna
    Yau, Thomas
    Goebeler, Maria-Elisabeth
    Huetter-Kroenke, Marie Luise
    Perotti, Antonella
    Juif, Pierre-Eric
    Lu, Darlene
    Barys, Louise
    Cremasco, Viviana
    Pelletier, Marc
    Evans, Helen
    Fabre, Claire
    Doi, Toshikiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [7] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [8] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    BLOOD, 2010, 116 (21) : 1350 - 1351
  • [9] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Mettu, Niharika B.
    Ulahannan, Susanna, V
    Bendell, Johanna C.
    Garrido-Laguna, Ignacio
    Strickler, John H.
    Moore, Kathleen N.
    Stagg, Robert
    Kapoun, Ann M.
    Faoro, Leonardo
    Sharma, Sunil
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
  • [10] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
12345